DTC User Fees Shot Down; Advertisers Face More Perilous Future
This article was originally published in RPM Report
Executive Summary
The good news for advertisers: FDA will have more resources for pre-review of ads in 2008, funded by the taxpayers. The bad news: what happens in 2009?
You may also be interested in...
Off-Label Communication Growth: Could FDA Afford To Police It?
Another user fee for the US drug agency could help pay for research of off-label uses, but lack of resources could be a regulatory problem.
DTC Held Hostage? FDA Pre-Review of TV Ads May Delay Rx Campaigns
FDA is proposing changes to its regulation of television advertising for prescription drugs with a mandatory pre-review of ads for certain products. The agency says it has the resources to complete all reviews on time. But stakeholders worry that the draft requirements would delay campaigns and make DTC advertising more expensive. It’s not like there’s a good alternative: jumping the gun on DTC carries its own set of risks.
DTC Public Health Slant: A Winning Formula With FDA Commissioner Hamburg
FDA Commissioner Margaret Hamburg is not taking the easy way out when she discusses DTC, even in front of Congressional critics of the practice. She does not treat DTC as primarily a regulatory problem for the agency; instead she likes to focus on the public health potential of DTC.